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Abstract 
Background: In the present work we described the recombinant production and characterization of heterodimeric 
construction ZnT8-Arg-Trp325 fused to thioredoxin using a high-performance expression system such as Escherichia 
coli. In addition, we apply this novel recombinant antigen in a non-radiometric method, with high sensitivity, low 
operational complexity and lower costs.
Results: ZnT8 was expressed in E. coli as a fusion protein with thioredoxin (TrxZnT8). After 3 h for induction, recom-
binant protein was obtained from the intracellular soluble fraction and from inclusion bodies and purified by affinity 
chromatography. The expression and purification steps, analyzed by SDS-PAGE and western blot, revealed a band 
compatible with TrxZnT8 expected theoretical molecular weight (≈ 36.8 kDa). The immunochemical ability of TrxZnT8 
to compete with  [35S]ZnT8 (synthesized with rabbit reticulocyte lysate system) was assessed qualitatively by incubat-
ing ZnT8A positive patient sera in the presence of 0.2–0.3 μM TrxZnT8. Results were expressed as standard deviation 
scores (SDs). All sera became virtually negative under antigen excess (19.26–1.29 for TrxZnT8). Also, radiometric quan-
titative competition assays with ZnT8A positive patient sera were performed by adding TrxZnT8 (37.0 pM–2.2 µM), 
using  [35S]ZnT8. All dose–response curves showed similar protein concentration that caused 50% inhibition (14.9–
0.15 nM for TrxZnT8). On the other hand, preincubated bridge ELISA for ZnT8A detection was developed. This assay 
showed 51.7% of sensitivity and 97.1% of specificity.
Conclusions: It was possible to obtain with high-yield purified heterodimeric construction of ZnT8 in E. coli and it 
was applied in cost-effective immunoassay for ZnT8A detection.
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Background
Zinc transporter 8 (ZnT8) is a multipass transmembrane 
protein which has been identified as a novel autoantigen 
in patients with diabetes mellitus (DM), such as in type 
1 DM and in latent autoimmune diabetes of the adults 
(LADA) [1, 2]. It is a 369 amino acid protein, encoded by 
the SLC30A8 gene located in the chromosome 8q24.11. 
ZnT8 transports zinc ions from the beta-cell cytoplasm 
into insulin-secretory vesicles where they are essential for 
the proper storage and secretion of insulin [3]. Genome-
wide association studies analyzing susceptible/protec-
tive loci for type 2 DM revealed that a nonsynonymous 
single nucleotide polymorphism (SNP) in SLC30A8 
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(rs13266634 C>T) is associated with the disease [4]. This 
SNP changes arginine (Arg) to tryptophan (Trp) at posi-
tion 325, with a higher risk of developing the disease 
when the allele C (Arg325) is present.
Among the major autoantibodies employed in the 
diagnosis of autoimmune DM, autoantibodies to ZnT8 
(ZnT8A) is the most recently described humoral marker, 
complementing those already used such as insulin/proin-
sulin autoantibodies (IAA/PAA), glutamic acid decarbox-
ylase autoantibodies (GADA), and insulinoma associated 
protein tyrosine phosphatase 2 autoantibodies (IA-2A).
Wenzlau et  al. and other authors have reported that 
ZnT8-reactive sera mostly recognize the C-terminal 
domain of the molecule (amino acids 268–369) [1, 5]. 
ZnT8A have been detected in more than 60% of patients 
with type 1 DM [1, 2, 6–11] and in more than 10% of 
adult-onset diabetic patients [2, 8, 12], increasing the 
sensitivity in the screening of autoimmunity. Therefore, 
ZnT8A constitutes an additional prevalent marker to the 
preexisting triad, enabling the appropriate classification 
of diabetic patients as autoimmune DM and improving 
the efficacy of treatment.
The reference method for detection of ZnT8A is the 
radioligand binding assay (RBA); the antibody standardi-
zation program (DASP) demonstrated that this method 
achieved high sensitivity and specificity [13]. However, 
this assay includes a recombinant radiolabeled autoan-
tigen produced by cell-free protein expression systems, 
which is environmentally inappropriate, expensive to 
produce or unsustainable for wide application in labora-
tories or clinical settings.
We have previously characterized ZnT8A from type 
1 diabetic patients and non-obese adult-onset diabetic 
patients employing different ZnT8 antigenic variants, 
since the C-terminal domain of the ZnT8 include the 
variant residue at amino acid 325. In that work, we con-
cluded that the heterodimeric construction ZnT8-Arg-
Trp325 showed higher prevalence and signal levels and 
increased dynamic range in RBA for ZnT8A detection in 
both group of patients, therefore we decided to continue 
working with this antigenic construction [2]. Although 
there are commercial ELISA kits for ZnT8A detection, 
most of them do not mention their specificity and sensi-
tivity parameters. In particular, ELISA RSR™ZnT8 Ab™ 
kit reports 97% specificity and 76% of sensitivity in IASP 
2015 (RSR Limited, UK). However, none of these kits 
indicate the ZnT8 construction employed.
Given the need for improved and less expensive ZnT8A 
assays, in the present work we described the recombinant 
production and characterization of the heterodimeric 
construction ZnT8-Arg-Trp325 fused to thioredoxin 
(Trx) using a high-performance expression system such 
as Escherichia coli. Additionally, in this work, we apply 
this novel recombinant antigen in a non-radiometric 
method, with high sensitivity, low operational complexity 
and lower costs such as ELISA.
Results
Expression of ZnT8 as a fusion protein with thioredoxin 
in E. coli
Recombinant TrxZnT8 was expressed in both strains of 
E. coli, GI698 and GI724. Efficient TrxZnT8 production 
was achieved after 3 h of protein expression induction in 
both strains. Western blot (WB) analysis of intracellular 
soluble fraction (ISF) and inclusion bodies (IB) with poly-
clonal serum to Trx showed one band with the expected 
molecular weight (MW, ≈  36.8  kDa) for the full-length 
engineered protein, whereas such bands were absent in 
the ISF and IB from non-transformed bacteria under 
the same experimental conditions (Additional file 1: Fig-
ure S1). The highest levels of protein expression were 
obtained after 3 h of induction in ISF from strain GI698 
and in IB from strain GI724.
TrxZnT8 from the intracellular soluble fraction of E. coli 
GI698
Purification of TrxZnT8 from the intracellular soluble fraction
Recombinant TrxZnT8 was purified from the ISF of E. 
coli strain GI698 after 3  h of induction. The procedure 
was based on an affinity chromatography in which the 
Trx portion of TrxZnT8 binds to the resin by its catalytic 
domain containing vicinal dithiols. This one-step purifi-
cation separated most contaminant proteins with little or 
no significant loss of TrxZnT8 relying on the high capac-
ity of the in-house made resin. Figure  1 depicts SDS-
PAGE and WB of different stages of purification. Based 
on the quantification of the 100 mM 2ME fraction (lanes 
5–6) bands, the purification yielded ≈ 1.25 mg of 72.0–
74.0% pure TrxZnT8/L of culture medium.
Biochemical characterization of TrxZnT8
In order to estimate the MW of TrxZnT8, an SDS-PAGE 
with MW calibrators (bovine albumin, ovalbumin, car-
bonic anhydrase and trypsin inhibitor) was performed. 
A calibration curve of log MW vs.  Rf was constructed 
(log MW = − 0.0806 × Rf + 5.071,  R2 = 0.9960) and the 
unknown MW of TrxZnT8 was interpolated. An experi-
mental MW (38,474  Da) compatible to the theoretical 
MW (36,847 Da) was obtained (4.4% error, which is a sat-
isfactory accuracy for this method) [14].
Mass spectrometry analysis of TrxZnT8 verified the 
agreement of the MW of our expressed chimera with the 
expected value (actual mass 37,042.770  Da; theoretical 
mass 36,847.200 Da) (Fig. 2a). Besides, purified TrxZnT8 
was also subjected to proteolytic digestion with trypsin 
or chymotrypsin. The peptide profile obtained after each 
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digestion was analyzed by Orbitrap mass spectrom-
etry, achieving 73.6% total coverage (34.3% for trypsin 
and 62.7% for chymotrypsin) of TrxZnT8 (341 residues) 
(Fig.  2b), considering high confidence peptides only; 
when low confidence peptides were not filtered, 91.50% 
coverage of the theoretical composition of the protein 
was accounted for.
Immunochemical characterization of TrxZnT8
In order to test the ability of TrxZnT8 to react with 
ZnT8A, a quantitative competition assay was per-
formed in which variable concentrations of TrxZnT8 
were added (Fig.  3a). Five sera ZnT8A(+) from type 1 
diabetic patients were used. The experimental data were 
fitted to the log [inhibitors] vs. response–variable slope 
(four parameters) equation using GraphPad Prism ver-
sion 6.01. The TrxZnT8 concentration that caused 50% 
inhibition  (IC50) was calculated for each serum. All 
dose–response curves showed similar  IC50 (ranging from 
9.55  ×  10−9 to 3.43  ×  10−8  M), indicating comparable 
TrxZnT8 immunoreactivity with ZnT8A.
In addition, inhibition assays were performed (Fig. 3b). 
Sera from 29 type 1 diabetic patients that scored positive 
by the reference method, RBA (with  [35S]-ZnT8), were 
used [2, 12]. Also, 20 control sera were included in order 
to set a cut-off value. All patient sera tested were ZnT8A 
(+) with median SDs of 34.91, range 7.84–159.32 and 
cut-off value for positivity SDs =  3.0. A significant dif-
ference between sera from type 1 diabetic patients and 
healthy human individuals was observed (Unpaired 
samples Mann–Whitney U test, p  <  0.0001). All type 1 
diabetic patient sera became virtually negative under 
antigen excess: median SDs changed from 34.91 to 0.23 
(range −  1.14 to 4.90) with TrxZnT8 excess (Wilcoxon 
test for paired samples, p < 0.0001).
TrxZnT8 from inclusion bodies of E. coli GI724
Purification of TrxZnT8 from inclusion bodies
TrxZnT8 was also expressed in E. coli strain GI724 after 
3  h of induction. The protein from IB was solubilized 
with 8  M urea in 0.1  M Tris, pH  8.5. After ON refold-
ing, facilitated by a disulphide reduction–reoxidation 
procedure, TrxZnT8 was purified by affinity chroma-
tography in which the Trx portion of TrxZnT8 was rec-
ognized by the anti-Trx antibodies present in the resin. 
Figure  4 depicts SDS-PAGE and WB of different frac-
tions, from solubilization to purification. The one-step 
purification separated most contaminant proteins with 
little or no significant loss of TrxZnT8 relying on the high 
capacity of the in-house made resin. The purification 
yielded ≈ 2.20 mg of 95.0–97.0% pure TrxZnT8/L of cul-
ture medium.
Immunochemical characterization of TrxZnT8
Competitive quantitative and qualitative assays were also 
performed for TrxZnT8 from IB in order to evaluate any 
distortion in epitopes caused during the solubilization 
and refolding procedures. The immunochemical identi-
ties between TrxZnT8 from ISF and from IB were ana-
lyzed and expressed in terms of parallelism. As seen in 
Fig. 5a, when using a pool of ZnT8A + human sera, par-
allelism and identity between curves was achieved (one 
curve adequately fits all data, alpha = 0.05,  R2 = 0.8796). 
Furthermore, quantitative competition assays were per-
formed with six ZnT8A positive sera from type 1 dia-
betic patients (Fig.  5b). The experimental data were 
fitted to the log (inhibitors) vs. response–variable slope 
(four parameters) equation using GraphPad Prism ver-
sion 6.01. The  IC50 was calculated for each serum. All 
dose–response curves showed similar  IC50 (ranging from 
1.46 ×  10−10 to 1.49 ×  10−8  M), indicating comparable 
TrxZnT8 immunoreactivity with ZnT8A and similar to 
TrxZnT8 from ISF.
The inhibition assay for TrxZnT8 from IB was per-
formed by incubating 33 type 1 diabetic patient sera 
in the presence of 290  nM TrxZnT8 (Fig.  5c). All 
Fig. 1 Purification of TrxZnT8 from ISF by affinity chromatography. 
Analysis of TrxZnT8 fractions at different stages of purification by a 
SDS-PAGE (12.1% T, 6.0% C, 1 mm, under reducing conditions, stained 
with Coomassie Brilliant Blue R-250) and b WB revealed with a rabbit 
polyclonal serum to thioredoxin as primary antibody. In a and b, 
lane 1 corresponds to total ISF from transformed E. coli strain GI698, 
lane 2: unbound material, lane 3 and 4: washes with increasing 2ME 
concentrations (1 and 5 mM), lanes 5 and 6: 100 mM consecutive elu-
ates of purified TrxZnT8. Arrows indicate the electrophoretic mobility 
of TrxZnT8
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tested patient sera were ZnT8A positive with a SDs of 
19.26 ±  10.01 (mean ±  SD), median 18.82, range 5.17–
38.02 and a cut-off value for positivity SDs  =  3.0. Sera 
from type 1 diabetic patients differed significantly from 
healthy human samples (unpaired t test with Welch 
correction, p  <  0.0001). All patient sera became virtu-
ally negative (comparable to healthy individuals) under 
antigen excess: mean SDs changed from 19.26 to 1.29 
(median 0.95, range −  1.20 to 8.75) with cold TrxZnT8 
excess (Student t test for paired samples, p < 0.0001).
Immunochemical characterization of TrxZnT8‑biotin
Competitive quantitative and qualitative assays were 
also performed for TrxZnT8-biotin in order to evalu-
ate any distortion in epitopes caused by biotynilation. 
The immunochemical identities between TrxZnT8 and 
TrxZnT8-biotin were analyzed and expressed in terms 
of parallelism. As seen in Fig.  6a, when using a pool of 
ZnT8A+ human sera, parallelism and identity between 
curves were achieved (one curve adequately fits all data, 
alpha  =  0.05,  R2  =  0.9673). The inhibition assay for 
TrxZnT8-biotin was performed by incubating 32 Type 1 
diabetic patient sera in the presence of 280 nM TrxZnT8-
biotin (Fig.  6b). All tested sera were ZnT8A positive 
with an SDs of 19.26  ±  10.01 (mean  ±  SD), median 
18.82, range 11.07–38.02 and a cut-off value for positiv-
ity SDs = 3.0. It can be observed that sera from Type 1 
diabetic patients differed significantly from healthy con-
trol samples (unpaired t test with Welch correction, 
p  <  0.0001). All patient sera became virtually negative 
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Fig. 2 Biochemical characterization of TrxZnT8. a Mass spectrometry analysis of recombinant TrxZnT8. The box indicates the experimental peak 
corresponding to TrxZnT8. b TrxZnT8 scheme (above) and sequence (below). In the scheme, N-terminal Trx fraction, the linker peptide and the ZnT8 
fragment in the C-terminal of the construction are detailed, and the corresponding peptides fragments identified by Orbitrap Mass Spectrometry 
are highlighted in grey in the diagram. Also, the TrxZnT8 sequence is represented: underlined and highlighted in bold are those fragments identi-
fied by Orbitrap Mass Spectrometry considering high confidence peptides
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(comparable to healthy control individuals) under antigen 
excess: mean SDs changed from 19.21 to 1.03 (median 
0.33, range −  2.38 to 8.30) with cold TrxZnT8-biotin 
excess (Student t test for paired samples, p < 0.0001).
Immunoassay for ZnT8A detection using TrxZnT8
The preincubated-bridge ELISA (pb-ELISA) protocol was 
evaluated using human sera spanning a wide range of 
ZnT8A reactivity. In the pb-ELISA protocol the autoan-
tibodies in serum samples (n =  62) bind divalently and 
form a bridge between immobilized TrxZnT8 and liquid 
phase biotinylated TrxZnT8.
The sensitivity was calculated as the percentage of type 
1 diabetic patients that scored positive, and analytical 
sensitivity was calculated as the percentage of patients 
RBA positive that were positive by pb-ELISA. The speci-
ficity was calculated as 100% minus the percentage of 
normal human sera detected as positive.
Results obtained by pb-ELISA are shown in Fig. 7a, sig-
nals were expressed as SDs. Out of 62 type 1 DM patients 
analyzed, 32 sera were positive (51.6% sensitivity), with 
SDs ranging from −  1.24 to 8.37, median 1.67 and cut-
off value for positivity SDs = 1.5. Out of the 51 ZnT8A 
positive sera by RBA, 29 scored positive by pb-ELISA, 
whereas 22 were negatives. These results indicated that 
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Fig. 3 Immunochemical characterization of TrxZnT8 from ISF. a Dose–response curves for 5 ZnT8A RBA positive type 1 diabetic patient sera 
incubated with different concentrations of TrxZnT8. Each curve includes best-fit values from the log (inhibitor) vs. response–variable slope (four 
parameters) equation: correlation coefficient data  (R2),  IC50 values and approximation to the affinity constant of ZnT8A  (Ka) calculated as the inverse 
of  IC50. b Inhibition capacity of TrxZnT8 assessed in 29 ZnT8A RBA positive type 1 diabetic patient sera in the absence (B) or presence (C) of TrxZnT8. 
Twenty control sera were used in order to set a cut-off value (A). The binding was expressed as SDs, and the dotted line represents the cut-off value
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pb-ELISA had an analytical sensitivity of 56.9% for this 
sera collection. It is noteworthy that pb-ELISA detected 
positive 3 (4.8%) type 1 diabetic patients that RBA no. 
When evaluating healthy human sera, the specificity was 
97.1%. Populations significantly differed for median anti-
body levels (Mann–Whitney U test, p < 0.0001).
Figure  7b depicts a statistical comparison of RBA and 
pb-ELISA results from diabetic patients and healthy indi-
viduals. Despite the differences in physical–chemical prin-
ciples of the techniques, the correlation between both 
methods was significant (Spearman’s coefficient, rs = 0.399; 
p ˂ 0.001). Moreover, the agreement between the two immu-
noassays was 79.4%, with kappa statistic of 0.54 (Additional 
file 2: Table S1), representing good to fair agreement. Per-
formance of pb-ELISA was analyzed using receiver oper-
ating characteristic (ROC) analysis and the area under the 
curve (AUC) of ROC curve was 0.7845 (Fig. 7c).
Discussion
In previous works, it was described that the detec-
tion of ZnT8A, together with GADA, IA-2A and IAA, 
increases the diagnostic sensitivity of autoimmune DM 
[2, 15]. Unlike GAD and IA-2, ZnT8 is a highly specific 
β cell antigen; therefore, the presence of ZnT8A reveals, 
although indirectly, a specific damage of these cells. Even 
though radiometric methods have an excellent perfor-
mance in the diagnostic support of DM, the employ-
ment of radioactive isotopes is falling out of use because 
of their multiple disadvantages (high costs, waste man-
agement difficulties, low applicability in laboratories, 
centralization of determinations, etc.). That is why, the 
search for inexpensive and reliable alternative assays for 
the detection of ZnT8A has been of crucial in the last few 
years. The methods most widely used include solid phase 
immunoassays which require large amounts of antigen 
for their development and routine application. In this 
sense, most extensively applied and widely used prokar-
yotic host for the production of recombinant proteins 
is the E. coli by diverse research groups and also in the 
private sectors [16, 17]. This expression system is simple, 
versatile due to the high amount of cloning vectors and 
host strains available, and implies a rapid generation of 
biomass at low cost.
Consistent with prior observations [5, 18], the ZnT8A 
workshop results highlighted the superior sensitivity of 
ZnT8-Arg-Trp325 assays measuring antibodies simul-
taneously to both arginine and tryptophan polymorphic 
variants compared to assays using each monomeric vari-
ant alone, a performance that was achieved without sac-
rificing specificity [13]. In addition, in a previous work 
we concluded that the heterodimeric construction ZnT8-
Arg-Trp325 showed higher prevalence and signal levels 
and increased dynamic range in RBA for ZnT8A detec-
tion [2]. For these reasons, we decided to express this 
antigenic construction in E. coli. Cheng et  al. expressed 
two C-terminal fragment of the ZnT8 antigen in E. coli 
alternatively containing Arg or Trp at position 325 [19]. 
Moreover, Kawasaki et al., expressed a dimeric C-termi-
nal domain consisting of amino acids 275–369 [325Trp] 
and amino acids 275–369 [325Arg] with C-terminal 
6-His tag in Saccharomyces cerevisiae strain c13ABYS86 
using galactose for induction [20].
In this work, the heterodimeric construction of ZnT8 
was successfully expressed as a fusion protein with 
thioredoxin in the ISF of E. coli strain GI698 at 20  °C. 
The thioredoxin moiety allowed the one-step purification 
by an arsine derivative affinity chromatography yield-
ing ≈ 1.25 mg of protein/L of culture medium with 72.0–
74.0% of purity. In addition, Trx-ZnT8 was recovered 
from IB of E. coli strain GI724 induced at 37 °C, subjected 
to in  vitro refolding and purified by affinity chroma-
tography, yielding  ≈  2.20  mg of protein/L of culture 
medium, 95.0–97.0% pure. Because the highest concen-
tration and highest purity of the chimera was obtained 
from IB, these were selected as a more viable option for 
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Fig. 4 Purification of TrxZnT8 from IB by affinity chromatography. 
Analysis of TrxZnT8 fractions at different stages of purification by a 
SDS-PAGE (12.1% T, 6.0% C, 1 mm, under reducing conditions, stained 
with Coomassie Brillant Blue R-250) and b WB revealed with a rabbit 
polyclonal serum to thioredoxin as primary antibody. Lane 1 corre-
sponds to total cell lysate from transformed E. coli strain GI724, lane 2 
TrxZnT8 from IB solubilized with 8 M urea, lane 3 TrxZnT8 in oxidative 
refolding buffer, lane 4 unbound material, and lane 5 purified TrxZnT8 
from IB. Arrows indicates the electrophoretic mobility of TrxZnT8
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production of the recombinant protein. The amount of 
protein obtained with this methodology was suitable for 
the development of solid phase ZnT8A immunoassays; 
in fact, the result of a standard purification protocol may 
allow passive adsorption of more than 170 96-well poly-
styrene microplates. The first quality control step was to 
verify if TrxZnT8 had the theoretical expected MW. The 
analysis of the purified protein by SDS-PAGE and MS 
rendered results that coincided, within the experimental 
error, with the theoretical MW values calculated from 
the sequence. In addition, upon performing MS analysis 
after proteolytic digestion, sequence coverage of 73.6% 
was achieved over the 341 residues constituting the het-
erodymeric construction of TrxZnT8, which is a suitable 
percentage to accomplish the autoantigen identification.
Immunochemical studies of TrxZnT8 from ISF allowed 
us to demonstrate that the chimera was able to dis-
place the binding of radiolabeled eukaryotic ZnT8 from 
ZnT8A, thus confirming the integrity of epitopes in the 
recombinant antigen, which is a critical requirement for 
ZnT8A recognition. It is noteworthy that the  IC50 values 
obtained for 5 sera were in the range from 9.55 ×  10−9 
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Fig. 5 Immunochemical characterization of TrxZnT8 from IB. a Dose–response curves for a pool of 5 ZnT8A RBA positive type 1 diabetic patient 
sera for different concentrations of TrxZnT8 from ISF (closed circle, dotted line) and TrxZnT8 from IB (open circle, solid line). b Dose–response curves 
for six ZnT8A RBA positive type 1 diabetic patient sera incubated with different concentrations of TrxZnT8 from IB. Each curve includes best-fit 
values from the log (inhibitor) vs. response–variable slope (four parameters) equation: correlation coefficient data  (R2),  IC50 values and approxima-
tion to the affinity constant of ZnT8A  (Ka) calculated as the inverse of  IC50. c Inhibition capacity of TrxZnT8 assessed in 33 ZnT8A RBA positive type 1 
diabetic patient sera in the absence (B) or presence (C) of TrxZnT8. Twenty control sera were used in order to set a cut-off value (A). The binding was 
expressed as SDs, and the dotted line represents the cut-off value
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to 3.43 ×  10−8  M, which correlates with literature data 
(~ 1 × 10−9 M) [21]. Since the calculated  IC50 for ZnT8A 
were, within the limits of experimental error, the same 
for TrxZnT8 and these previously published data for 
other variants of ZnT8 from E. coli, it can be specu-
lated that the epitopes are not affected during prokary-
otic expression and Trx fusion. Furthermore, with a 
larger number of ZnT8A positive patient sera, we dem-
onstrated that they were able to recognize recombinant 
TrxZnT8, displacing the radioactively labeled eukary-
otic antigen under TrxZnT8 excess. When TrxZnT8 was 
recovered from IB, immunochemical identity with the 
chimera obtained from ISF was demonstrated by RIA, 
according to the general principles of immunochemical 
cross reactivity [22]. Moreover, the calculated  IC50 for 6 
ZnT8A positive sera were similar to those obtained with 
TrxZnT8 from ISF. In addition, competitive qualitative 
assays showed that all patient sera became virtually nega-
tive under TrxZnT8 excess recovered from IB.
Since TrxZnT8 could be expressed in a simple prokary-
otic system with high yields and purity, and it was prop-
erly identified and immunoreactive against ZnT8A 
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positive patient sera, we proceeded to apply this protein 
in non-radiometric methods for ZnT8A detection. In 
order to increase the possibilities for immunoassay devel-
opment, TrxZnT8 was biotinylated. When the immuno-
chemical behavior of TrxZnT8-biotin was studied, the 
dose–response curves generated by RIA showed iden-
tity between TrxZnT8 and its biotinylated counterpart. 
Furthermore, competitive qualitative assays showed that 
almost all patient sera became negative under TrxZnT8-
biotin excess. All these results indicate that the recogni-
tion of TrxZnT8 and the biotinylated protein by ZnT8A 
was the same; therefore, it could be deduced that the 
biotinylation did not alter critical epitopes for the inter-
action with ZnT8A.
Most conventional ELISA for measuring antibodies are 
based on surface-bound antigen and detection of total 
bound IgG with labeled xenogeneic anti-immunoglobulin 
antibodies. Frequently, the use of such labels increases 
the background- to- signal ratio. It was proposed that one 
way to reduce the background signal is to use the labeled 
specific antigen to detect bound antibody [23]. This also 
allows to employ undiluted sera increasing assay sen-
sitivity. In the present work we proceeded to optimize 
pb-ELISA, the first described solid phase immunoas-
say with colorimetric detection for the determination of 
ZnT8A using a heterodimeric construction of C-termi-
nal domain of ZnT8 (carrying Arg and Trp at position 
325) expressed in E. coli. In this sense, it is important to 
emphasize that none of the commercial kits specify the 
antigenic construction employed. So it is not possible to 
establish if these kits detect antibodies directed against 
structural epitopes generated by ZnT8 dimerization, as it 
was previously demonstrated by our group [2].
The pb-ELISA protocol, based on ZnT8A crosslinking 
of immobilized TrxZnT8 and liquid-phase TrxZnT8-
biotin, was highly specific (97.1%) but had lower sensitiv-
ity (51.6%) than RBA. The analytical sensitivity (56.9%) 
was calculated in order to compare the performance of 
pb-ELISA vs. the RBA, being the latter validated in the 
IASP 2012 and 2015 workshops. It is difficult to com-
pare the performance of this assay with those of previ-
ous studies where ZnT8A is detected [19, 20] because 
different antigens were used, as well as different patient 
populations and healthy control individuals (with vari-
ables such as number, ethnicity and, possibly, sample 
matrix). The lack of correlation between solid-phase and 
liquid-phase assays has been previously reported and dis-
cussed [24–27]. In this sense, different thermodynamic 
principles apply to ELISA and RBA, since in the latter 
antigen–antibody reaction occurs in the liquid phase, 
in high dilution and near the equilibrium; meanwhile in 
ELISA the interaction occurs in solid phase, where the 
amount of immunocomplexes is highly dependent on 
antibodies concentration. In fact, in T1DM, autoantibod-
ies concentration is really low (in the order of  10−12 M), 
turning their detection into an analytical challenge using 
solid phase assays, especially for sensitivity limitations. 
Then, as expected, there was a low correlation between 
the results obtained by ELISA protocol and RBA. How-
ever, despite the differences in the physical–chemical 
principles of the techniques, the agreement between the 
two immunoassays was 79.4%, with kappa statistic of 
0.54. Moreover, the value of AUC achieved for pb-ELISA 
(0.7845) was considered acceptable.
Based on not requiring the use of radioisotopes and the 
semiautomated high-throughput assay format, the pb-
ELISA should facilitate large-scale autoantibody screen-
ing. However, a weakness of the study is the limited 
number of subjects. A larger population should be ascer-
tained in order to better characterize the performance of 
the immunoassay. In addition, it would be interesting to 
evaluate this assay in other patient populations such as 
adult-onset diabetic patients in order to better charac-
terize the performance of the assay and its application in 
this group of patients.
These results may provide a basis for further research 
aimed at the simultaneous detection of multiple autoan-
tibodies for the prediction, classification, monitor-
ing, and prognosis of T1DM. In this sense, methods for 
ZnT8A detection by flow cytometry based on the use of 
polystyrene microspheres are currently being developed 
in our laboratory [28]. This assay has the potential of 
simultaneous determination of the main humoral mark-
ers in autoimmune DM. Therefore, multiplex testing will 
facilitate high-throughput screening of T1DM in the gen-
eral population.
Conclusions
The approach reported herein should be accessi-
ble to many laboratories and allow the production of 
TrxZnT8 at low cost and effort. In turn, the availability 
of properly folded ZnT8 would encourage researchers 
to improve present and develop new, low-cost tests for 
ZnT8A detection as well as in clinical trials with ZnT8 
immunomodulation.
Methods
Sera collection
Human sera collection
Sera were obtained from 83 selected type 1 diabetic 
patients spanning a wide range of ZnT8A reactivity. This 
group included Argentinian children and adolescents 
admitted to the Nutrition Service at Gutierrez National 
Pediatric Hospital (Buenos Aires, Argentina) from May 
2013 to April 2016, with a mean age of 9.8 years at diag-
nosis, median age of 9.0, range 2–17  years and male/
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female: 44/39. Serum samples were collected before or 
within 72 h of starting insulin treatment. Type 1 DM was 
diagnosed according to WHO criteria [29]. The protocol 
was approved by the Ethical Committee of the Gutierrez 
National Pediatric Hospital and parental consent were 
obtained.
Healthy human sera (n  =  70, mean age of 29.7  years 
with median age of 25, range 16–80 and male/female: 
36/34) were obtained from Argentinian healthy subjects 
without personal or family history of DM or autoimmune 
disease. The collection of serum samples was approved 
by the Ethics Committee of the José de San Martín Clini-
cal Hospital, University of Buenos Aires (UBA), Buenos 
Aires, Argentina. All subjects were informed about the 
purpose of the study, and a signed consent for study par-
ticipation was obtained.
Rabbit polyclonal sera against Trx
Antibodies to Trx were obtained by immunizing two 
New Zealand white rabbits with 1  mg of recombinant 
Trx emulsified in complete Freund’s adjuvant. The initial 
injection was followed by booster injections with 1 mg of 
the mentioned protein in incomplete Freund’s adjuvant 
at 3-week intervals. The rabbits were bled 15  days after 
booster dose. The immunoreactivity of polyclonal sera 
to Trx was tested by indirect-ELISA using Trx-coated 
polystyrene plates and by western blot. All animals were 
housed under specific conditions according to the “Guide 
for the Care and Use of Laboratory Animals” by the 
National Research Council of the National Academies 
(USA); experiments were performed in compliance with 
the Argentinian animal protection laws and approved 
by the “Prof. Ricardo A. Margni” Humoral Immunity 
Studies Institute (IDEHU), National Research Council 
(CONICET-UBA).
Expression of TrxZnT8 in Escherichia coli
Expression vector
Unless otherwise indicated, standard molecular biol-
ogy protocols were used according to Sambrook et  al. 
[30]. Restriction enzymes, Pfu polymerase and T4 ligase 
were from Promega (Madison, WI, USA). The coding 
sequence of dimeric C-terminal domain of human ZnT8 
consisting of amino acids 268–369 [Arg325] and amino 
acids 268–369 [Trp325] were optimized for prokaryotic 
expression. The ZnT8 optimized nucleotide sequence 
was synthesized by GenScript (GenScript Corporation, 
Piscataway, NJ, USA; http://www.GenScript.com) includ-
ing KpnI and XbaI sites at the 3′ and 5′ ends, respectively. 
The synthesized construct (682  bp) was obtained from 
GenScript in plasmid pUC57 and maintained in E. coli 
strain JM109 (Promega, Madison, WI, USA). After prop-
agation and purification of the vector with QIAprep spin 
Miniprep Kit (QIAGEN, Hilden, Germany), ZnT8 con-
struct was digested with KpnI and XbaI and ligated into 
the pTrxFus linearized vector (Invitrogen, Carlsbad, CA, 
USA). The quality of the new vector encoding the fusion 
protein TrxZnT8 (Additional file  3: Figure S2) was cor-
roborated by sequencing (Macrogen Inc, Seoul, Korea).
Escherichia coli transformation and protein expression
Competent E. coli strains GI724  (ATCC® 55151™) and 
GI698 (Invitrogen, Carlsbad, CA, USA) were trans-
formed by electroporation with pTrxZnT8. Bacteria were 
cultured at 30  °C in 0.2% casein amino acids, 0.5% glu-
cose, 1  mM  MgCl2 and 100  µg/mL ampicillin, and pro-
tein expression was induced with 100 µg/mL Trp at 37 °C 
for GI724 or 20 °C for GI698, at different times (1.5, 3.0 
and 16.0 h).
Escherichia coli disruption and intracellular protein 
isolation
Total cell lysate (TCL) Bacteria from 1 mL culture were 
collected by centrifugation, suspended in 0.2  mL of 
sodium dodecyl sulphate-polyacrylamide gel electropho-
resis (SDS-PAGE) sample buffer (0.05 M Tris–HCl, 12.0% 
glycerol, 0.005% bromophenol blue, 4.0% SDS, 4.0% 
2-mercaptoethanol—2ME, pH 6.8) and boiled for 5 min.
Intracellular soluble fraction (ISF) Bacteria from 200 mL 
culture were collected by centrifugation, suspended in 
4  mL of lysis buffer (50  mM Tris–HCl, 100  mM NaCl, 
1  mM EDTA, pH 7.0) and sonicated in the presence of 
1 mM 2ME and protease inhibitors (0.1% aprotinin and 
2  mM phenylmethylsulphonyl fluoride). After sonica-
tion, Triton X-100 was added to a final concentration of 
0.1%, and the mixture was incubated for 10 min at 0 °C. 
The ISF was separated from the IB by centrifugation at 
15,000×g for 10 min at 4 °C.
Inclusion bodies (IB) IB from 200  mL of culture were 
washed with 2  M urea in 0.1  M Tris, pH 8.5, and solu-
bilized with 8  M urea in 0.1  M Tris, pH 8.5. Oxida-
tive refolding was initiated by dialysis at 4  °C against 
0.5 M l-arginine, 50 mM Tris–HCl, 5 mM EDTA, 5 mM 
reduced glutathione and 0.5  mM oxidized glutathione, 
pH 9.5 [31, 32].
Purification of TrxZnT8 by affinity chromatography
Purification of TrxZnT8 from the Intracellular soluble fraction
TrxZnT8 from the ISF was purified by means of affin-
ity chromatography following the protocol previously 
described [31, 33]. Briefly, the resin was based on an 
agarosa support covalently modified with phenylars-
ine oxide, which permitted the binding of proteins con-
taining vicinal dithiol residues, as it occurs in Trx [34]. 
The lysate (4  mL) was added to the resin, previously 
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equilibrated in lysis buffer (≈  4  mL) and activated 
with 4 column volumes (CV) of lysis buffer containing 
20  mM 2ME, and the resulting suspension was incu-
bated for 1.5 h at 4 °C. The resin was poured into a col-
umn and washed sequentially with 6 CV of lysis buffer, 
6 CV of lysis buffer containing 1 mM 2ME and 3 CV of 
lysis buffer containing 5 mM 2ME. Bound proteins were 
eluted with several 2 mL aliquots of lysis buffer contain-
ing 100 mM 2ME. The protein concentration in purified 
fractions was determined using the Coomasie Plus (Brad-
ford) Assay kit. Aprotinin was added to a final concentra-
tion of 0.1%.
Purification of TrxZnT8 from the inclusion bodies
After overnight (ON) refolding of IB, the buffer was 
exchanged by gel filtration on a PD10 column (Amersham 
Biosciences, Piscataway, NJ) equilibrated with phosphate 
saline buffer (PBS, 1.5 mM  KH2PO4, 8.1 mM  Na2HPO4, 
0.14  M NaCl, 2.7  mM KCl, pH 7.4) and TrxZnT8 was 
purified by affinity chromatography. Briefly, the resin was 
based on Anti-Trx Ig-Sepharose CL-4B prepared by cou-
pling purified Anti-Trx immunoglobulins to Sepharose 
CL-4B activated with CNBr (Pharmacia-LKB Biotech-
nology, Uppsala). TrxZnT8 from IB (2  mL) was added 
to the PBS equilibrated resin (2 mL) and the suspension 
was incubated ON at 4  °C. The resin was poured into a 
column and washed with 10 CV of PBS. Elution was per-
formed with 0.53% diethylamine in distilled water, pH 
11.0; 2  mL fractions were collected in tubes containing 
2  mL of 1  M Tris–HCl pH 7.4 to neutralize the eluates 
and buffer exchange to PBS was made by using ZEBA 
desalt spin column (Pierce Biotechnology, Rockford, IL, 
USA) according to the manufacturer’s instructions.
The protein concentration in purified fractions was 
determined using the Coomasie Plus (Bradford) Assay 
kit. Aprotinin was added to a final concentration of 0.1%.
Biotinylation of TrxZnT8
Two mL of the purified fusion protein from IB were 
subjected to buffer exchange to PBS using a ZEBA 
desalt spin column (Pierce Biotechnology, Rockford, IL, 
USA) according to the manufacturer’s instructions. The 
desalted protein was then incubated for 2 h at 0 °C with 
a 300-fold molar excess of sulfo-NHS-biotin (Pierce Bio-
technology, Rockford, IL, USA). Free biotin was removed 
on a new ZEBA desalt spin column.
Biochemical characterization of TrxZnT8
Molecular weight determination by SDS‑PAGE
The general SDS-PAGE procedure for MW estima-
tion consisted in separating several conventional stand-
ard proteins with known MW (Amersham Pharmacia 
Biotech, Little Chalfont Buckinghamshire, England) 
in parallel with a TrxZnT8 sample in a 10.0% T, 6.0% C 
acrylamide gel with 1.5 mm thickness and under reduc-
ing conditions [35]. The standard proteins were used in 
order to generate a curve correlating MW and migration 
in the gel (relative mobility or  Rf), from which the MW of 
TrxZnT8 sample was estimated.
Mass spectrometry analysis
In order to assess total protein MW, affinity purified 
TrxZnT8 from ISF was subjected to mass spectrometry 
(MS) analysis. One µL aliquot of the sample of TrxZnT8 
was spotted onto an AnchorChip (Bruker, Billerica, MA, 
USA). One  µL of an oversaturated solution of sinapinic 
acid in 30/70/0.1% acetonitrile/water/TFA was added 
to the sample and left to crystallize by air-drying. Sam-
ples were analyzed on a Bruker Microflex MALDI-TOF 
(Bruker, Billerica, MA, USA). Aiming to further charac-
terize and identify the protein, TrxZnT8 was subjected 
to proteolytic digestion and MS analysis. Concisely, 
the sample was dissolved in 50  mM  NH4HCO3 buffer, 
pH 8.0; a volume equivalent to 20  µg was subjected to 
disulfide bond reduction, with 20 mM dithiothreitol for 
45 min at 56  °C, and alkylation with 20 mM iodoaceta-
mide for 45 min at room temperature (RT) in the dark. 
The sample was then diluted to a final concentration of 
1  M urea. Finally, trypsin and chymotrypsin proteolytic 
digestion were performed separately and samples were 
analyzed by nanoHPLC (EASY-Spray Accucore, Thermo 
scientific, West Palm Beach, FL, USA) coupled to a mass 
spectrometer with Orbitrap technology (Q-Exactive, 
Thermo Scientific, West Palm Beach, FL, USA; at Cen-
tro de Estudios Químicos y Biológicos por Espectromet-
ría de Masa-CEQUIBIEM- CONICET-UBA, Argentina), 
enabling both separation and identification of peptides. 
Ionization of samples was made by electrospray (EASY-
SPRAY, Thermo Scientific, West Palm Beach, FL, USA) 
and data analysis was performed by the Proteome Dis-
coverer software version 1.4, Thermo Scientific. Cover-
age percentages were calculated based on the number of 
identified peptides/total number of peptides.
Immunochemical characterization of TrxZnT8
Western blot analysis
Total E. coli lysates, ISF and IB were analyzed by SDS-
PAGE [35] and western blot (WB). For comparison, all 
SDS-PAGE lanes in each gel contained proteins recov-
ered from the same amount of cells. Protein bands were 
transferred to nitrocellulose membranes and unoccu-
pied binding sites were blocked by incubation with 2.0% 
skim milk in Tris buffer saline (TBS, 0.05  M Tris–HCl, 
0.15 M NaCl, pH 7.5) for 2 h at RT. After 3 washing steps 
with 0.05% Tween 20 in TBS (TBS-T), membranes were 
incubated ON at RT with polyclonal sera to Trx diluted 
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1/200 in 2.0% skim milk, 0.05% Tween 20 in TBS (TBS-
MT) and then washed five times with TBS-T. Bound anti-
bodies were visualized by incubation with horseradish 
peroxidase (HRP)-conjugated goat antibodies to rabbit 
IgG (Jackson ImmunoResearch Laboratories, Inc., West 
Grove, PA) diluted 1/2000 in TBS-MT, followed by the 
addition of alpha-chloronaphthol (Sigma-Aldrich, Inc., St 
Louis, MO) and 10 vol  H2O2.
Qualitative and quantitative competition assays
Radioimmunoassay protocol Quantitative competition 
assays were performed by standard Radioimmunoassays 
(RIA). The  [35S]ZnT8 tracer was obtained by in  vitro 
transcription/translation of the cDNA for the dimeric 
construct encoding C-terminal domain of human ZnT8, 
with amino acids 268–369 [Arg325] and amino acids 
268–369 [Trp325], using a rabbit reticulocyte lysate sys-
tem (Promega, Madison, WI, USA) in the presence of 
 [35S]-methionine (New England, Nuclear, Boston, MA, 
USA), according to the manufacturer´s instructions 
[2, 12]. The RIA was carried out by incubating 5  µL of 
ZnT8A(+) type 1 diabetic patient sera in duplicate with 
10,000  cpm of  [35S]ZnT8 in the presence of serial con-
centrations (37.0 pM–2.2 µM) of purified TrxZnT8 from 
ISF or IB in a final volume of 60  µL. After ON incuba-
tion, 50  μL of 40.0% protein A-Sepharose 4B FF (GE 
Healthcare Biosciences, Uppsala, Sweden) in RIA buffer 
(0.02 M Tris–HCl, 0.15 M NaCl, 0.1% Tween 20, pH 7.4) 
were added and incubated for 2 h at RT on an end-over-
end shaker. Subsequently, samples were allowed to settle 
and the supernatants were discarded in order to isolate 
immunocomplexes. Pellets were washed three times with 
200 µL of RIA buffer and once with 200 µL of 0.2 M NaCl 
in RIA buffer. Finally, pellets were suspended in 100  µL 
of 1.0% SDS and supernatants were carefully transferred 
to vials for scintillation counting (1  min/tube). Results 
for each sample were calculated as Bound % (B %) = 100 
× (bound cpm/total cpm). Inhibitory Dose–response 
curves [log  (inhibitor) vs. response–variable slope (four 
parameters)] were fitted to the mathematical function:
where B corresponds to B% measurements,  B0 is the B% 
at zero concentration of unlabelled antigen, B/B0min and 
B/B0max are the minimal and maximal response, respec-
tively and the parameter  IC50 represents the concen-
tration of TrxZnT8 that gave a response half between 
B/B0min and B/B0max. Hill Slope describes the steep-
ness of the family of curves. The same protocol was 
B/B0 = B/B0min + (B/B0max − B/B0min)/(
1+ 10
[(log IC50−log TrxZnT8 dose)∗Hill Slope]
)
performed for TrxZnT8-biotin, in serial concentrations 
of 172.0 pM–0.2 µM.
Inhibition assay The ability of TrxZnT8 to compete with 
 [35S]ZnT8 for the binding to antibodies was assessed qual-
itatively by incubating sera from 30 ZnT8A(+) type 1 dia-
betic patients with the tracer in the presence of purified 
fusion protein, either from the ISF (190 nM) or recover 
from IB (290 nM). Briefly, 5 µL of human sera were incu-
bated ON at 4  °C with 10,000  cpm of  [35S]ZnT8 in the 
absence or presence of unlabelled TrxZnT8 in a final vol-
ume of 60 µL in RIA buffer. Immunocomplexes were iso-
lated with protein A-Sepharose 4B FF; pellets were washed 
and suspended in 1.0% SDS, as described in the RIA pro-
tocol. The radioactivity of supernatants was counted. 
Results for each sample (with or without TrxZnT8) were 
calculated as B  %, and expressed as Standard Deviation 
scores (SDs) =  (B% − Bc%)/SDc, where  Bc% is the mean 
B% of healthy human sera and  SDc its standard deviation. 
The same protocol was followed for TrxZnT8-biotin in 
the presence of antigen excess (280 nM).
ZnT8A detection by radioligand binding assay
ZnT8A were assessed by radioligand binding assay (RBA) 
as previously described [2, 12]. Briefly, 5  µL of human 
sera were incubated ON at 4  °C with 10,000 cpm of the 
 [35S]ZnT8 in a final volume of 60 µL in RIA buffer. Subse-
quently, isolation of immune complexes was carried out 
by addition of 50 μL 40% protein A-Sepharose 4B FF in 
RIA buffer. Pellets were washed three times with 200 μL 
of RIA buffer and once with 200  μL of 0.2  M NaCl in 
RIA buffer. Finally, pellets were suspended in 100  μL of 
1% SDS and supernatants were carefully transferred to 
vials for scintillation counting. Results were expressed 
as precision units, SDs. Thirty healthy human sera were 
included in each assay demonstrating that BC% was nor-
mally distributed. The whole procedure was validated in 
the Islet Autoantibody Standardization Program (IASP) 
2015 where our laboratory achieved 68% sensitivity and 
97.8% specificity (Lab. 0519).
ZnT8A detection by preincubated bridge ELISA (pb‑ELISA)
Reagents
The coating buffer was PBS, the blocking buffer was 
2% skim milk in PBS, the washing buffer was PBS con-
taining 0.05% Tween 20 (PBS-T) and the preincuba-
tion buffer was 0.1% aprotinin and 2% skim milk in 
PBS-T. Reagent dilutions were prepared in 2% skim 
milk, in PBS-T (PBS-MT). Avidin– HRP was purchased 
from Jackson ImmunoResearch Laboratories, Inc. The 
3,3′,5,5′-tetramethyl-benzidine/H2O2 (Single Component 
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TMB Peroxidase EIA Substrate Kit, BioRad, Hercules, 
CA, USA) was employed as the chromogenic substrate. 
Except when otherwise indicated, incubations were per-
formed at RT, washing steps were performed with PBS-T 
and 50 μL per well were added in each incubation step.
pb‑ELISA protocol
The protocol employed was based on those previously 
described [20, 36], with minor modifications. Briefly 
polystyrene microplates (Maxisorp, NUNC, Rorkilde, 
Denmark) were coated ON at 4  °C with 0.2  µg of puri-
fied TrxZnT8 from IB per well, washed three times with 
PBS, blocked for 1.5 h with 200 µL of blocking solution 
per well, and washed five times. Separately, in Eppendorf 
tubes a sample volume of 40 µL was incubated ON at 4 °C 
with 20  µL of preincubation buffer containing 3.8  ng of 
TrxZnT8-biotin. Then, the preincubates were transferred 
to the microplates coated with TrxZnT8 and incubated 
for 1.5 h. Microplates were washed five times, and bound 
TrxZnT8-biotin was detected by the addition of Avidin-
HRP diluted 1/600. After washing (four times plus one 
final wash with PBS), the chromogenic substrate was 
added and plates were incubated in the dark. The colour 
reaction was stopped with 4 N  H2SO4.
Statistical analysis
The statistical analysis was performed using GraphPad 
Prism software, version 6.01 for Windows (GraphPad 
Software, San Diego California, USA, http://www.graph-
pad.com). The immunochemical identities and parallel-
ism between inhibitory dose–response curves obtained 
with TrxZnT8 from ISF and from IB and TrxZnT8-biotin 
were analyzed by comparing B/B0min, B/B0max, Hill slope 
and  IC50 values by the extra sum-of-squares F test com-
parison method. Normal distribution of data was ana-
lyzed by the D’Agostino and Pearson omnibus normality 
test. The selection of optimal cut-off values was based on 
curves constructed by plotting the calculated specificity 
and sensitivity of each protocol against the cut-off values. 
Statistical significance was evaluated using parametric 
tests: paired samples Student t test and unpaired samples 
Student t test with Welch correction, or non-parametric 
tests: Wilcoxon matched-pairs signed rank test or Mann–
Whitney U test for unpaired data, when applicable. Per-
formance of pb-ELISA was analyzed using ROC analysis 
and the AUC was evaluated. Spearman coefficient of cor-
relation (rs) was calculated to evaluate inter-assay cor-
relation. The kappa statistic was used to measure the 
strength of agreement between the pb-ELISA and RBA 
results, with a kappa statistic value of 0.75 representing 
excellent agreement, 0.40–0.75 representing good to fair 
agreement and 0.40 representing poor agreement [37, 
38].
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